drugset / Trial / NCT02587364

Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

NCT02587364 ↗

Phase 1 Completed 50 enrolled NeuroBo Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the multiple-dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.

Timeline

Start
1999-04
Primary completion
1999-09
Completion
1999-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcabene Small molecule 50 mg —
Subject Gemcabene Small molecule 150 mg —
Subject Gemcabene Small molecule 450 mg —
Subject Gemcabene Small molecule 600 mg —
Subject Gemcabene Small molecule 750 mg —
Subject Gemcabene Small molecule 900 mg —

Indications